Skip to content
EntityQ2359711· pop 15· linked from 482 articles

Also known as BEIH, N-isonicotinyl hydrazide, N-benzyl-beta-(isonicotinylhydrazino)propionamide, N-benzyl-beta-(isonicotinoylhydrazine)propionamide, 2-[2-(benzylcarbamoyl)ethyl]hydrazide, isonicotinic acid, N-[2-(benzylcarbamyl)ethylamino]isonicotinamide, 2-[2-(benzylcarbamoyl)ethyl]hydrazide isonicotinic acid, 2-(2-(benzylcarbamyl)ethyl)hydrazide isonicotinic acid

Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant. It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.

Research

1,644 papers

via PubMed

~1 min read

Encyclopedic overview

2 sections
Contents
  • See also
  • References

Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant. It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.

Side effects include agitation and insomnia, less frequently dry mouth, dizziness, blurred vision, and hypomania, and rarely leukopenia and hepatitis. As with other MAOIs, a hypertensive crisis can be triggered by co-ingestion of tyramine. It is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. The recommended dosage range is 75 to 200 mg per day, with maintenance doses as low as 12.5 mg every other day.

Excerpted from Wikipedia’s “nialamide” article, available under the CC BY-SA 4.0 licence.